Latest News & Features
Americas
Bayer Healthcare and Mylan have settled their differences over a generic version of Bayer’s liver cancer drug Nexavar (sorafenib tosylate). 30 October 2017
Americas
The US Department of Justice has dropped its case against a dual citizen of Canada and China who was charged in connection with attempting to steal trade secrets. 30 October 2017
Big Pharma
The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva. 27 October 2017
Americas
Merck Sharp & Dohme (MSD) has suffered a loss at the US Court of Appeals for the Federal Circuit, after the court affirmed an earlier finding of obviousness. 27 October 2017
Americas
Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir. 26 October 2017
Americas
The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology. 26 October 2017
Americas
CRISPR offers ground-breaking opportunities for tackling diseases and genome defects, but its use must be carefully managed to avoid the obvious ethical problems that will arise, as Sanchith Shivakumar of Anand and Anand reports. 26 October 2017
Americas
Owners of biotech inventions may find Mexico an attractive country in which to apply for patent protection because of its non-restrictive patent law and its practical approach to examination, as Eder Gutiérrez of Clarke Modet & Co outlines. 26 October 2017
Americas
Those working in the field of genetic sequence must clearly understand the subtleties of sequence searching, in order to avoid the risks of infringement and invalidity, as Ellen Sherin of GQ Life Sciences finds out. 26 October 2017
Big Pharma
Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe. 26 October 2017